Rapid Screening Test Detects Chlamydial Infection
By LabMedica International staff writers Posted on 26 Mar 2013 |
A rapid nonculture method for detection of Chlamydia trachomatis has been developed based on the measurement of specific enzymatic activity in urogenital tract specimens.
The method is based on the level of the activity of α-mannosidase, a gylcoside hydrolase involved in the maturation and degradation of glycoprotein-linked oligosaccharides, on its specific chromogen.
Scientists at Zhengzhou University (China) evaluated the performance of a method, which measured the α-mannosidase activities of C. trachomatis serotype D strain and 29 standard strains related to clinical urogenital pathogens. They also assayed 553 urogenital tract specimens via cell culture method and ligase chain reaction method (LCR), adopting an expanded gold standard.
For the 203 male cases, three urethral discharge specimens from 151 outpatients or three prostate massage liquid specimens from 52 outpatients were collected with sterile rayon swabs. For the 350 female cases, three cervical secretion specimens were collected from 232 outpatients, or three vaginal secretion specimens were collected from 118 outpatients, with sterile rayon swabs using vaginal forceps.
The enzymatic method was based on the substrate 6-chloro-3-indolyl-α-D-mannoside and the chromogenic reagent contained fast violet B salt (J&K Chemical; Shanghai, China; www.jkchemical.com). The result was considered to be positive when the optical density (OD) at 512 nm was greater than 0.150, if the color changed from colorless to red or brown after 15 minutes of incubation at 37 °C. Cell culture and LCR method were used to evaluate the clinical performance of the enzymatic method.
Of the 553 clinical samples, 132 samples were positive with the OD ranging from 0.161 to 1.955, and 421 samples were negative with OD ranging from 0.013 to 0.142. The sensitivity of the enzymatic method was 91.5%, and the specificity of this method was 90.0%.
The authors concluded that they had demonstrated that there were no significant differences between the enzymatic method and the reference method if prostate specimens were excluded. Therefore, α-D-mannosidase activity may be a useful marker for C. trachomatis in urogenital tract specimens, with many advantages, such as its speed, ease of use, convenience, and specialized equipment is not essential. The study was published on January 24, 2013, in, the BioMed Central journal BMC Infectious Diseases.
Related Links:
Zhengzhou University
J&K Chemical
The method is based on the level of the activity of α-mannosidase, a gylcoside hydrolase involved in the maturation and degradation of glycoprotein-linked oligosaccharides, on its specific chromogen.
Scientists at Zhengzhou University (China) evaluated the performance of a method, which measured the α-mannosidase activities of C. trachomatis serotype D strain and 29 standard strains related to clinical urogenital pathogens. They also assayed 553 urogenital tract specimens via cell culture method and ligase chain reaction method (LCR), adopting an expanded gold standard.
For the 203 male cases, three urethral discharge specimens from 151 outpatients or three prostate massage liquid specimens from 52 outpatients were collected with sterile rayon swabs. For the 350 female cases, three cervical secretion specimens were collected from 232 outpatients, or three vaginal secretion specimens were collected from 118 outpatients, with sterile rayon swabs using vaginal forceps.
The enzymatic method was based on the substrate 6-chloro-3-indolyl-α-D-mannoside and the chromogenic reagent contained fast violet B salt (J&K Chemical; Shanghai, China; www.jkchemical.com). The result was considered to be positive when the optical density (OD) at 512 nm was greater than 0.150, if the color changed from colorless to red or brown after 15 minutes of incubation at 37 °C. Cell culture and LCR method were used to evaluate the clinical performance of the enzymatic method.
Of the 553 clinical samples, 132 samples were positive with the OD ranging from 0.161 to 1.955, and 421 samples were negative with OD ranging from 0.013 to 0.142. The sensitivity of the enzymatic method was 91.5%, and the specificity of this method was 90.0%.
The authors concluded that they had demonstrated that there were no significant differences between the enzymatic method and the reference method if prostate specimens were excluded. Therefore, α-D-mannosidase activity may be a useful marker for C. trachomatis in urogenital tract specimens, with many advantages, such as its speed, ease of use, convenience, and specialized equipment is not essential. The study was published on January 24, 2013, in, the BioMed Central journal BMC Infectious Diseases.
Related Links:
Zhengzhou University
J&K Chemical
Latest Microbiology News
- Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more